Device Trial Radar · NCT03466918
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
May 23, 2018
Primary completion
Jul 3, 2019
Study completion Jun 19, 2024
Sponsor
- Lead sponsor
- Edwards LifesciencesPublic (EW)
- Sponsor type
- Industry
- First posted
- Mar 15, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.
Conditions
- Aortic Stenosis
- Symptomatic Aortic Stenosis
- Aortic Regurgitation
Interventions
SAPIEN 3 THV with the Commander delivery systemDevice
Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause MortalityTime frame: 30-days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital, CAMS&PUMC
Beijing, China
WestChina Hospital, Sichuan University
Chengdu, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.